Zhengyan Zhang1, Samantha Fye2, Ingrid B Borecki1, Janet S Rader3. 1. Washington University School of Medicine in St. Louis, 660 South Euclid Ave., St. Louis, MO 63011, USA. 2. Medical College of Wisconsin, 9200W. Wisconsin Ave., Milwaukee, WI 53226, USA. 3. Medical College of Wisconsin, 9200W. Wisconsin Ave., Milwaukee, WI 53226, USA. Electronic address: jrader@mcw.edu.
Abstract
OBJECTIVE: The immune system is critical for controlling the progression of HPV cervical disease and the development of cancer. This study aimed to identify cervical cancer susceptibility alleles in candidate immune-modulating genes. METHODS: Our family-based study involved a cohort of 641 probands (women with ICC/CIN III) and their biologic parents or siblings (641 trios). In the discovery phase (stage 1), involving 288 of the trios, 80 tag single nucleotide polymorphisms (SNPs) in 11 immune-modulating genes (IFNG, IFNGR1, IFNGR2, JAK1, JAK2, STAT1, STAT6, IL12A, TNF, LTA and LTB) were evaluated on the GoldenGate platform. We used the combined dataset for a total of 641 trios (stage 2) and the Taqman platform to validate the SNPs that had proved significant in the discovery dataset. The transmission disequilibrium test was used to detect significant shifts in allelic transmissions in the datasets. RESULTS: Two SNPs in JAK2 and one SNP in STAT6 showed significant allelic association with cervical cancer in the stage 1 discovery dataset and were replicated in the larger joint analysis stage 2 dataset (JAK2 rs10815144, P=0.0029 and rs12349785, P=0.0058; and STAT6 rs3024971, P=0.0127). An additional SNP in exon 19 of JAK2 (rs2230724) was also examined in the combined dataset due to its strong linkage disequilibrium (LD) with rs10815144. It was also significant (P=0.0335). CONCLUSIONS: Our results suggest an association of SNPs in JAK2 and STAT6 with cervical cancer. This association should be investigated in additional cervical cancer populations.
OBJECTIVE: The immune system is critical for controlling the progression of HPV cervical disease and the development of cancer. This study aimed to identify cervical cancer susceptibility alleles in candidate immune-modulating genes. METHODS: Our family-based study involved a cohort of 641 probands (women with ICC/CIN III) and their biologic parents or siblings (641 trios). In the discovery phase (stage 1), involving 288 of the trios, 80 tag single nucleotide polymorphisms (SNPs) in 11 immune-modulating genes (IFNG, IFNGR1, IFNGR2, JAK1, JAK2, STAT1, STAT6, IL12A, TNF, LTA and LTB) were evaluated on the GoldenGate platform. We used the combined dataset for a total of 641 trios (stage 2) and the Taqman platform to validate the SNPs that had proved significant in the discovery dataset. The transmission disequilibrium test was used to detect significant shifts in allelic transmissions in the datasets. RESULTS: Two SNPs in JAK2 and one SNP in STAT6 showed significant allelic association with cervical cancer in the stage 1 discovery dataset and were replicated in the larger joint analysis stage 2 dataset (JAK2rs10815144, P=0.0029 and rs12349785, P=0.0058; and STAT6rs3024971, P=0.0127). An additional SNP in exon 19 of JAK2 (rs2230724) was also examined in the combined dataset due to its strong linkage disequilibrium (LD) with rs10815144. It was also significant (P=0.0335). CONCLUSIONS: Our results suggest an association of SNPs in JAK2 and STAT6 with cervical cancer. This association should be investigated in additional cervical cancer populations.
Authors: Alina Deshpande; John P Nolan; P Scott White; Yolanda E Valdez; William C Hunt; Cheri L Peyton; Cosette M Wheeler Journal: J Infect Dis Date: 2005-02-08 Impact factor: 5.226
Authors: Isabel Duarte; Alexandra Santos; Hugo Sousa; Raquel Catarino; Daniela Pinto; Ana Matos; Deolinda Pereira; José Moutinho; Paulo Canedo; José Carlos Machado; Rui Medeiros Journal: Biochem Biophys Res Commun Date: 2005-08-26 Impact factor: 3.575
Authors: Clara Bodelon; Margaret M Madeleine; Lisa G Johnson; Qin Du; Mari Malkki; Effie W Petersdorf; Stephen M Schwartz Journal: Gynecol Oncol Date: 2011-11-28 Impact factor: 5.482
Authors: Erika M Kwon; Sarah K Holt; Rong Fu; Suzanne Kolb; Gabrielle Williams; Janet L Stanford; Elaine A Ostrander Journal: Cancer Epidemiol Date: 2012-04-26 Impact factor: 2.984
Authors: Shehnaz K Hussain; Margaret M Madeleine; Lisa G Johnson; Qin Du; Denise A Galloway; Janet R Daling; Mari Malkki; Effie W Petersdorf; Stephen M Schwartz Journal: Int J Cancer Date: 2013-02-12 Impact factor: 7.396
Authors: Dan R Robinson; Yi-Mi Wu; Shanker Kalyana-Sundaram; Xuhong Cao; Robert J Lonigro; Yun-Shao Sung; Chun-Liang Chen; Lei Zhang; Rui Wang; Fengyun Su; Matthew K Iyer; Sameek Roychowdhury; Javed Siddiqui; Kenneth J Pienta; Lakshmi P Kunju; Moshe Talpaz; Juan Miguel Mosquera; Samuel Singer; Scott M Schuetze; Cristina R Antonescu; Arul M Chinnaiyan Journal: Nat Genet Date: 2013-01-13 Impact factor: 38.330
Authors: Janet S Rader; Shirng-Wern Tsaih; Daniel Fullin; Miriam W Murray; Marissa Iden; Michael T Zimmermann; Michael J Flister Journal: Int J Cancer Date: 2019-01-04 Impact factor: 7.396